Wealth doesn’t appear overnight — it’s the result of smart habits, consistent effort and disciplined financial choices that should align with your retirement plan. Getting rich is rarely about sudden windfalls, but rather daily actions, such as prioritizing financial education, setting goals, living within your means and diversifying your investment portfolio. Trending Now: I’m a Self-Made Millionaire: 6 Steps I Took To Become Rich on an Average Salary Up Next: Clever Ways To Save Money That Actually Work ...

Core Viewpoint - MicroPort Medical (00853) has announced a restructuring of its cardiac rhythm management business, which is expected to enhance operational clarity and support future growth [1] Group 1: Business Restructuring - MicroPort Medical's subsidiary, MicroPort Cardiac Rhythm Management (CRM), plans to merge with CRM Cayman, which will become a wholly-owned subsidiary focused on arrhythmia management solutions [1] - The pre-transaction equity value of CRM Cayman is estimated at $680 million [1] Group 2: Shareholding and Strategic Partnerships - MicroPort Medical currently holds a 46.12% stake in MicroPort Cardiac Rhythm Management and a 50.13% stake in CRM Cayman [1] - The introduction of Shanghai Industrial Holdings as a strategic shareholder is expected to bolster the company's financial and business development [1] Group 3: Financial Outlook - Analysts from JPMorgan believe that the merger will eliminate significant uncertainties that have been affecting the company [1] - Bank of America Securities anticipates that through cost control and divestment of non-core assets, the company could achieve profitability by the first half of 2026 [1] - Rapid growth in overseas business is expected to mitigate domestic market risks and provide long-term growth visibility [1]

30 September 2025 PayPoint PlcStrategic Investment in Collect+ by International Distribution Services Proposed Special Dividend and associated Share ConsolidationPublication of Circular and Notice of General Meeting PayPoint Plc and International Distribution Services (IDS), owner of Royal Mail, are pleased to announce the next stage in their partnership through a strategic investment in Collect+ to take a 49% ownership, with an investment of £43.9 million, valuing the Collect+ business at £90 million. Cur ...

Group 1 - Rongchang Biopharma's "Taitasip" is proposed for priority review by CDE for treating adult patients with primary IgA nephropathy, showing significant reduction in proteinuria levels [1] - "Taitasip" has already been approved for three indications in China, including myasthenia gravis, rheumatoid arthritis, and systemic lupus erythematosus, with a recent application for Sjögren's syndrome also accepted [1] Group 2 - Baiyunshan and Guangzhou Pharmaceutical Phase II Fund signed a strategic investment agreement to acquire over 144 million shares of Nanjing Pharmaceutical, making it the second-largest shareholder with an 11.04% stake [2] - This strategic investment aims to enhance market competitiveness through resource integration and synergy, potentially impacting Nanjing Pharmaceutical's governance structure and market performance [2] Group 3 - Pian Zai Huang's Chief Financial Officer Yang Haipeng resigned due to work adjustments, with Deputy General Manager He Wei temporarily taking over the CFO duties [3] - The long-term brand value and market position of Pian Zai Huang remain strong, and if the management transition is smooth, the impact on the company's long-term development may be limited [3] Group 4 - Former Chief Technology Officer of Kailai Ying, Hu Xinhui, has joined Hengrui Medicine as Vice President and Chief Technology Officer, indicating a strategic move to strengthen R&D capabilities [4] - Hu Xinhui's appointment is expected to bring new opportunities for Hengrui Medicine's R&D system upgrades, technological breakthroughs, and international development [4] Group 5 - The former Chairman of Guangzhou Pharmaceutical Group, Li Chuyuan, has been reported for violations of discipline and law, leading to his expulsion from the party and public office [5] - This incident highlights governance and internal oversight issues within Guangzhou Pharmaceutical Group, which may affect investor trust and subsequently impact its stock performance and market reputation [5]

9月28日晚间，南京医药（600713）披露关于签订《战略投资协议》的公告。 公司与广州白云山医药集团股份有限公司（以下简称"白云山"）及广州广药股权投资合伙企业（有限合 伙）（以下简称"广药二期基金"）签署《战略投资协议》。 目前，南京医药股票价格为4.88元/股，与现价相比，转让价格略有溢价。 白云山位于广州，公司是A+H上市公司，目前市值约413亿元。 公司主要从事：（1）中西成药、化学原料药、天然药物、生物医药、化学原料药中 间体的研究开发、 制造与销售；（2）西药、中药和医疗器械的批发、零售和进出口业务；（3） 大健康产品的研发、生 产与销售；及（4）医疗服务、健康管理、养生养老等健康产业投资等。 白云山是南派中药的集大成者，大南药板块主要为医药制造业务，下属共有 27 家医药制造企业与机 构，从事中西成药、化学原料药、化学原料 药中间体、生物医药和天然药物等的研发、制造与销售。 大健康板块主要为饮料、食品、保健品等产品的生产、研发与销售，主要从事的企业包括本公司下属子 公司王老吉大健康公司及王老吉药业等。 大商业板块主要为医药流通业务，包括医药产品、医疗器械、保健品等的批发、零售与进出口业务，主 ...

（原标题：港股异动 | 周大福创建(00659)再涨超4% 战略投资带动利润超预期 机构称派息符合预期） 消息面上，周大福创建近期发布截至6月底全年业绩，公司股东应占溢利上升4%至21.62亿港元。里昂 发布研报称，周大福创建下半财年经常性利润同比增长18%至14亿元，由于公司的战略投资带动更高贡 献，其表现较预期高出19%。末期息派0.35港元，同比持平，基本符合预期，公司亦建议进行十送一红 股。 此外，周大福创建宣布拟发行于2028年到期的22.18亿港元0.75%可交换债券，交换财产为其持有的首程 控股约10.0%的已发行股本。交易完成后，周大福创建将退出对首程控股的投资。中金表示，将此次交 易视为首程控股进一步优化其持股结构的重要契机；此次交易完成后，首程控股流动性将显著改善。 智通财经APP获悉，周大福创建(00659)再涨超4%，截至发稿，涨3.82%，报8.42港元，成交额4606.77万 港元。 ...

此外，周大福创建宣布拟发行于2028年到期的22.18亿港元0.75%可交换债券，交换财产为其持有的首程 控股约10.0%的已发行股本。交易完成后，周大福创建将退出对首程控股的投资。中金表示，将此次交 易视为首程控股进一步优化其持股结构的重要契机；此次交易完成后，首程控股流动性将显著改善。 周大福创建(00659)再涨超4%，截至发稿，涨3.82%，报8.42港元，成交额4606.77万港元。 消息面上，周大福创建近期发布截至6月底全年业绩，公司股东应占溢利上升4%至21.62亿港元。里昂 发布研报称，周大福创建下半财年经常性利润同比增长18%至14亿元，由于公司的战略投资带动更高贡 献，其表现较预期高出19%。末期息派0.35港元，同比持平，基本符合预期，公司亦建议进行十送一红 股。 ...

近日，西藏甘露藏药股份有限公司（以下简称"甘露藏药股份"）增资扩股引入战略投资者项目竞争性谈 判会议在西藏产权交易中心召开。根据谈判结果，甘露藏药股份与四家战略投资者签约，合计募资约 1.74亿元。 成功引进战略投资者，不仅是甘露藏药股份落实西藏自治区"格桑花行动"计划的关键举措，更标志着公 司上市进程迈出了里程碑式的一步。 甘露藏药股份本次引入的战略投资者堪称"战投天团"，涵盖国家级基金、世界500强医药国企、地方国 有投资平台以及金融机构。 签约仪式上，战略投资者代表——混改基金副总经理袁昊冉表示，未来将积极参与甘露藏药股份公司治 理，充分发挥自身优势，与甘露藏药股份在战略规划、业务拓展、资本运作等方面深度协同，共同将公 司打造成为更具市场竞争力和影响力的行业标杆。 甘露藏药股份相关负责人表示，成功引入四家实力雄厚的"战投天团"，是市场对甘露藏药股份未来发展 潜力的高度认可。公司未来将借助各战略股东在资本、产业、渠道、管理等方面的优势，在生产线扩 能、产业链完善、品牌保护和市场拓展等方面，进一步巩固和提升公司的核心竞争力，推动高质量发 展。据透露，公司战略投资者的选择紧扣"重点布局内地市场"的战略目标，瞄 ...

Group 1 - Intel Corp is experiencing an increase in stock price following reports of a strategic investment approach to Apple Inc, which was previously a major customer [1] - The semiconductor firm believes that an investment from Apple will help strengthen its business operations [1]

智通财经APP讯，泰坦科技(688133.SH)发布公告，为促进公司战略发展，进一步拓展公司业务领域， 借助专业投资机构的投资经验及资金优势，促进公司产业布局优化与完善，对公司未来的战略性投资和 并购能提供较好的行业资源、技术支持及投资标的选择，更好的推动公司的业务发展、协同创新和生态 构建，公司拟作为有限合伙人以自有资金出资2900万元至上海泰礼璟源创业投资合伙企业(有限合伙)(暂 定名，以最终工商注册名为准。简称"接力基金第七期")，基金主要从事新材料、科学服务等行业相关 早期科技类创业企业的投资。 ...